other material
confidence high
sentiment neutral
materiality 0.50
Provectus Biopharmaceuticals converts $542,500 in accrued director fees into Series D-1 Preferred Stock
PROVECTUS BIOPHARMACEUTICALS, INC.
- Board approved conversion of $542,500 in accrued directors' fees into 189,554 shares of Series D-1 Preferred Stock.
- Preferred Stock is convertible into 1,895,540 shares of Common Stock.
- Issuance satisfies outstanding cash fees, not under 2024 Equity Compensation Plan.
- Conversion effective as of June 30, 2026, based on May 14, 2026 Board approval.